First-Line Pembrolizumab Monotherapy for Advanced NSCLC With Programmed Death-Ligand 1 Expression Greater Than or Equal to 50%: Real-World Study Including Older Patients in Japan

First-Line Pembrolizumab Monotherapy for Advanced NSCLC With Programmed Death-Ligand 1 Expression Greater Than or Equal to 50%: Real-World Study Including Older Patients in Japan

Introduction: Pembrolizumab became available in Japan in February 2017 for first-line monotherapy of unresectable advanced and metastatic NSCLC with programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) greater than or equal to 50%. This retrospective chart review study aimed to describe re...

Full description

Bibliographic Details
Main Authors: Yasushi Goto, MD, PhD, Atsuhisa Tamura, MD, PhD, Hirotaka Matsumoto, MD, Kazutoshi Isobe, MD, PhD, Tomohiro Ozaki, MD, Melissa L. Santorelli, PhD, MPH, Kazuko Taniguchi, MS, Tetsu Kamitani, MD, PhD, Masato Irisawa, PhD, Kingo Kanda, MPharm, Machiko Abe, MS, Thomas Burke, PharmD, PhD, Hiroshi Nokihara, MD, PhD
Format: Article
Language:English
Published: Elsevier 2022-09-01
Series:JTO Clinical and Research Reports
Subjects:
Non–small cell lung cancer
Older adults
Pembrolizumab
Real-world progression-free survival
Survival
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364322001217

Internet

http://www.sciencedirect.com/science/article/pii/S2666364322001217

Similar Items